Skip to main content

Table 5 Impacts of anti-IL5/IL5R and anti-IgE therapy on upper respiratory tract findings and need for treatment in asthma patients receiving biologicals. The parameters were adjusted to match a 12-month period of biological therapy. Patients with discontinued biological therapy were included in the analyses

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

 

Anti-IL5/IL5R (Reslizumab, Mepolizumab, Benralizumab)

N = 38

 

Anti-IgE (Omalizumab)

N = 17

 

Baseline

Change

P

Baseline

Change

P

Courses of OCS (number/year) a

1.24 (0–8. SD 2.03)

−0.79 (−8–2. SD 2.14)

0.031

0.82 (0–3. SD 1.04)

−0.59 (−3–1. SD 1.03)

0.037

Courses of antibiotics (number/year)

0.94 (0–5. SD 1.26)

0.12 (−4–5. SD 1.99)

0.718

1.12 (0–4. SD 1.23)

−0.22 (− 3–7. SD 2.09)

0.674

Polypectomy (number)

1.37 (0–20. SD  3.29)

−1.24 (−20–1. SD 3.30)

0.028

1.59 (0–20. SD 4.67)

−1.41 (− 20–1. SD 4.69)

0.246

Ethmoidectomy (number)

0.76 (0–4. SD 0.87)

−0.71 (− 4–1. SD 0.94)

5.10 e− 05

0.29 (0–1. SD 0.46)

−0.12 (− 1–2. SD 0.68)

0.496

FESS (number) b

1.03 (0–4. SD 0.87)

− 0.95 (− 3–1. SD 0.89)

1.34 e− 07

1.12 (0–4. SD 1.13)

−0.82 (− 4–1. SD 1.25)

0.018

Polyps in nasal inspection (number, (%))

22 (58)

−9

0.038

7 (41)

−1

0.724

Mucous oedema in nasal inspection (number, (%))

19 (50)

−12

0.004

7 (41)

+ 4

0.169

  1. aOCS = per oral corticosteroid
  2. bFESS = Functional endoscopic sinus surgery